Navigation Links
Women More Likely Than Men to Avoid Amputation After Minimally Invasive Therapy for Blocked Leg Arteries

Women with below-the-knee artery blockages fare better than men when treated with minimally invasive endovascular therapy. Two years after endovascular treatment, 88 percent of women avoided amputation compared to 83 percent of men, according to a study of 277 patients.

(PRWEB) January 18, 2010 -- Women who are at risk of lower-leg amputation fare even better than men when they have minimally invasive treatment to open up the blocked arteries causing the problem, suggest results of a study being presented at the 22nd annual International Symposium on Endovascular Therapy (ISET).

Two years after receiving endovascular treatment – including angioplasty, stenting and atherectomy – nearly nine out of 10 (88 percent) of women in the study had avoided amputation, versus 83 percent of men.

“This study is the first to compare the outcomes of men and women being treated for blocked lower-leg arteries with endovascular therapy,” said Tejas Shah, M.D., research fellow at Mt. Sinai Medical Center, New York. “The results suggest endovascular therapy should be strongly considered in women with blocked arteries below the knee.”

The retrospective study involved review of all such procedures that took place at Mt. Sinai between July 1999 and November 2009 and included 152 men and 125 women. After two years, 46 percent of treated leg arteries in women remained open, compared to 30 percent in men. However, women experienced higher rates of blood clots forming at the access site of the treatment: nine percent of women vs. 0.6 percent of men experienced clotting, which is treated with blood thinners and may require a longer stay in the hospital.

Narrowed and blocked leg arteries are a common symptom of peripheral arterial disease (PAD). Like heart arteries, leg arteries can become clogged by plaque (fatty deposits) that slows or stops the flow of blood. About eight million Americans have PAD, according to the American Heart Association. PAD can cause pain while walking and, in extreme cases, lead to gangrene and the need for amputation of the toes, feet or legs, or even death.

These blockages can be treated several ways, including bypass – involving major surgery, lengthy incisions and general anesthesia – or minimally invasively by endovascular therapy. Several types of endovascular therapy are based on conventional balloon angioplasty in which a small cut is made in the groin and a thin tube, called a catheter, is advanced through the arteries to the site of the blockage in the legs. A tiny balloon is advanced to the blockage through the catheter and then inflated, compressing the plaque against the artery wall and opening the artery to allow better blood flow. In some cases, a tiny cage, called a stent, is left behind, which acts like scaffolding to keep the arteries propped open. Another method, called atherectomy, involves cutting out or vaporizing the plaque.

In the study, 104 men and 102 women had angioplasty alone, 29 men and 20 women had angioplasty and stenting and 48 men and 26 women had atherectomy. Some patients had more than one blockage treated. There was no difference in results between the various forms of endovascular therapy.

The International Symposium on Endovascular Therapy (ISET) is attended by more than 1,200 physicians, scientists, allied professionals and industry professionals from around the world. The meeting pioneered the use of live cases to promote the multidisciplinary treatment of cardiac and vascular disease by endovascular means. ISET is presented by the Baptist Cardiac & Vascular Institute, Miami. ISET 2010 is taking place Jan. 17-21 near Miami Beach, Fla. For more information, visit

Editor’s note: Study numbers are current as of January 12, 2010 and may change upon presentation at the ISET meeting.

Copies of the 2010 ISET news releases are available online at


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
3. KGI and Smith College Establish Leadership Forum for Women in Bioscience
4. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
5. ABCs Private Practice Inaccurately Portrays Serious Womens Health Condition
6. National Survey Shows Most Women Are Not Satisfied With Their Progesterone Treatment
7. Federally-Funded Study Shows More Women Can Avoid Hysterectomy for Common Problem
8. Georgia Reproductive Specialists is First in Southeast to Offer Pioneering Test of Womens Biological Clock
9. Barr and Ortho Womens Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation
10. Collaboration Sparks Creation of New Grand Rapids Laboratory Focused on Womens Health
11. deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women
Post Your Comments:
(Date:11/25/2015)... Studies reveal the differences in ... pave the way for more effective treatment for one of ...   --> --> Gum ... in cats, yet relatively little was understood about the bacteria ... been conducted by researchers from the WALTHAM Centre for Pet ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, ... will participate in a fireside chat discussion at the ... New York . The discussion is scheduled for ... .  A replay will be available ... Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications and ...
(Date:11/24/2015)... 2015 Cepheid (NASDAQ: CPHD ) today ... following conference, and invited investors to participate via webcast. ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ... New York, NY      Tuesday, December 1, 2015 ...
(Date:11/24/2015)... - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) (the "Company"), ... Toronto Stock Exchange, confirms that as of the date ... that would cause the recent movements in the Company,s ... About Aeterna Zentaris Inc. . ... Zentaris is a specialty biopharmaceutical company engaged in developing ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):